||Relevant Treatment Approaches
RB1 K240Sfs*22 TP53 R248W
Her2-receptor negative breast cancer
predicted - resistant
Fulvestrant + Palbociclib
In a clinical case study, RB1 K240Sfs*22 and TP53 R248W were identified in the circulating tumor DNA of a patient with estrogen receptor positive, progesterone receptor positive, and Erbb2 (Her2)-negative, invasive ductal carcinoma at the time of disease progression after 5 months of Ibrance (palbociclib) and Faslodex (fulvestrant) combination treatment (PMID: 29236940).